EP2307549A4 - INFLUENZA VIRUS TYPE (VLP) PARTICLES COMPRISING HEMAGGLUTININ - Google Patents

INFLUENZA VIRUS TYPE (VLP) PARTICLES COMPRISING HEMAGGLUTININ

Info

Publication number
EP2307549A4
EP2307549A4 EP09793741A EP09793741A EP2307549A4 EP 2307549 A4 EP2307549 A4 EP 2307549A4 EP 09793741 A EP09793741 A EP 09793741A EP 09793741 A EP09793741 A EP 09793741A EP 2307549 A4 EP2307549 A4 EP 2307549A4
Authority
EP
European Patent Office
Prior art keywords
vlp
hemagglutinin
particles
influenza virus
virus type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09793741A
Other languages
German (de)
French (fr)
Other versions
EP2307549A1 (en
Inventor
Aoust Marc-Andre D
Manon Couture
Frederic Ors
Sonia Trepanier
Pierre-Olivier Lavoie
Michele Dargis
Louis-Philippe Vezina
Nathalie Landry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicago Inc
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2008/001281 external-priority patent/WO2009009876A1/en
Priority claimed from PCT/CA2009/000032 external-priority patent/WO2009076778A1/en
Application filed by Medicago Inc filed Critical Medicago Inc
Priority to EP12181077.4A priority Critical patent/EP2570484B1/en
Publication of EP2307549A1 publication Critical patent/EP2307549A1/en
Publication of EP2307549A4 publication Critical patent/EP2307549A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/04—Intramolecular oxidoreductases (5.3) transposing S-S bonds (5.3.4)
    • C12Y503/04001—Protein disulfide-isomerase (5.3.4.1), i.e. disufide bond-forming enzyme
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F9/00—Arrangements for program control, e.g. control units
    • G06F9/06—Arrangements for program control, e.g. control units using stored programs, i.e. using an internal store of processing equipment to receive or retain programs
    • G06F9/46—Multiprogramming arrangements
    • G06F9/50—Allocation of resources, e.g. of the central processing unit [CPU]
    • G06F9/5005—Allocation of resources, e.g. of the central processing unit [CPU] to service a request
    • G06F9/5027—Allocation of resources, e.g. of the central processing unit [CPU] to service a request the resource being a machine, e.g. CPUs, Servers, Terminals
    • G06F9/505—Allocation of resources, e.g. of the central processing unit [CPU] to service a request the resource being a machine, e.g. CPUs, Servers, Terminals considering the load
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/65—Vector systems having a special element relevant for transcription from plants
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F2209/00—Indexing scheme relating to G06F9/00
    • G06F2209/50—Indexing scheme relating to G06F9/50
    • G06F2209/508—Monitor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Software Systems (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Theoretical Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
EP09793741A 2008-07-11 2009-07-02 INFLUENZA VIRUS TYPE (VLP) PARTICLES COMPRISING HEMAGGLUTININ Withdrawn EP2307549A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12181077.4A EP2570484B1 (en) 2008-07-11 2009-07-02 Influenza virus-like particles (VLPS) comprising hemagglutinin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CA2008/001281 WO2009009876A1 (en) 2007-07-13 2008-07-11 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
PCT/CA2009/000032 WO2009076778A1 (en) 2007-11-27 2009-01-12 Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
PCT/CA2009/000926 WO2010003225A1 (en) 2008-07-11 2009-07-02 Influenza virus-like particles (vlps) comprising hemagglutinin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP12181077.4A Division EP2570484B1 (en) 2008-07-11 2009-07-02 Influenza virus-like particles (VLPS) comprising hemagglutinin

Publications (2)

Publication Number Publication Date
EP2307549A1 EP2307549A1 (en) 2011-04-13
EP2307549A4 true EP2307549A4 (en) 2011-09-07

Family

ID=41507811

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09793741A Withdrawn EP2307549A4 (en) 2008-07-11 2009-07-02 INFLUENZA VIRUS TYPE (VLP) PARTICLES COMPRISING HEMAGGLUTININ
EP12181077.4A Active EP2570484B1 (en) 2008-07-11 2009-07-02 Influenza virus-like particles (VLPS) comprising hemagglutinin

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP12181077.4A Active EP2570484B1 (en) 2008-07-11 2009-07-02 Influenza virus-like particles (VLPS) comprising hemagglutinin

Country Status (15)

Country Link
EP (2) EP2307549A4 (en)
JP (1) JP5921884B2 (en)
KR (2) KR101956910B1 (en)
CN (1) CN102272308A (en)
AU (1) AU2009267759A1 (en)
BR (1) BRPI0915896A2 (en)
CA (1) CA2730185C (en)
EA (1) EA034733B1 (en)
ES (1) ES2525177T3 (en)
IL (1) IL210215A (en)
MX (1) MX2011000459A (en)
NZ (1) NZ590144A (en)
RU (1) RU2011105073A (en)
SG (1) SG187500A1 (en)
WO (1) WO2010003225A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076778A1 (en) 2007-11-27 2009-06-25 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
WO2009151407A2 (en) * 2008-06-14 2009-12-17 Veredus Laboratories Pte Ltd Influenza sequences
AU2009267769B2 (en) 2008-07-08 2015-07-16 Medicago Inc. Soluble recombinant influenza antigens
NZ590351A (en) 2008-07-18 2012-11-30 Medicago Inc HA1 domain totally or partially free of N-linked glycosylation operatively linked to a regulatory region
HUE039100T2 (en) 2009-06-24 2018-12-28 Medicago Inc Chimeric influenza virus-like particles comprising hemagglutinin
EP2477650B8 (en) * 2009-09-18 2019-10-09 FRAUNHOFER USA Inc. Virus like particles comprising target proteins fused to plant viral coat proteins
KR101773431B1 (en) 2009-09-22 2017-09-12 메디카고 인코포레이티드 Method of preparing plant-derived vlps
WO2012058762A1 (en) 2010-11-04 2012-05-10 Medicago Inc. Plant expression system
TWI526539B (en) 2010-12-22 2016-03-21 苜蓿股份有限公司 Method for producing viroid-like particles (VLP) in plants and VLP produced by the method
TWI620816B (en) 2011-03-23 2018-04-11 苜蓿股份有限公司 Plant derived protein recovery method
US9580475B2 (en) 2011-06-20 2017-02-28 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
AU2011373387B2 (en) 2011-07-18 2017-06-29 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
NZ622731A (en) 2011-09-30 2016-04-29 Medicago Inc Increasing virus-like particle yield in plants
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
BR112014011345A2 (en) * 2011-11-11 2017-05-16 Philip Morris Products Sa influenza virus-like particles (vlps) comprising nicotiana tabacum produced by hemagglutinin
WO2013119683A1 (en) * 2012-02-07 2013-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
CA2868330A1 (en) 2012-03-30 2013-10-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses
JP2015528285A (en) 2012-09-05 2015-09-28 メディカゴ インコーポレイテッド Production of picornavirus-like particles in plants
SG11201503989PA (en) * 2012-11-27 2015-06-29 Univ Pittsburgh Computationally optimized broadly reactive antigens for h1n1 influenza
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
ES2803508T3 (en) * 2013-03-28 2021-01-27 Medicago Inc Production of flu virus-like particles in plants
RU2699982C2 (en) * 2014-01-10 2019-09-11 Медикаго Инк. Enhancer elements cpmv
US10563213B2 (en) 2014-03-27 2020-02-18 Medicago Inc. Modified CPMV enhancer elements
RU2731295C2 (en) 2014-07-11 2020-09-01 Медикаго Инк. Modification of protein production in plants
WO2016168187A1 (en) * 2015-04-13 2016-10-20 The Regents Of The University Of Michigan Virus-like particles
AU2016270979B2 (en) * 2015-06-02 2020-11-12 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
JP2018524345A (en) 2015-07-02 2018-08-30 メディカゴ インコーポレイテッド Jasmonate pathway activator
CA3026096A1 (en) 2016-06-02 2017-12-07 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
JP6622825B2 (en) * 2018-01-25 2019-12-18 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Influenza A virus neutralizing antibody and method of use thereof
CN112400021A (en) 2018-03-14 2021-02-23 麦迪卡格公司 Plant expression enhancer
EP3814509A4 (en) 2018-06-27 2022-07-27 Medicago Inc. INFLUENZA VIRUS HEMAGGLUTININ MUTANTS
WO2020092207A1 (en) * 2018-10-28 2020-05-07 University Of Georgia Research Foundation Broadly reactive immunogens of influenza virus, compositions, and methods of use thereof
US20220135992A1 (en) * 2019-03-06 2022-05-05 Plantform Corporation T-dna vectors with engineered 5' sequences upstream of post-translational modification enzymes and methods of use thereof
WO2020181354A1 (en) 2019-03-14 2020-09-17 Mitsubishi Tanabe Pharma Corporation Endogenous plant expression enhancer
JP2020048568A (en) * 2019-11-22 2020-04-02 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Influenza a virus neutralizing antibodies and use methods thereof
KR102647829B1 (en) * 2020-04-22 2024-03-14 포항공과대학교 산학협력단 Production method for trimeric spike protein of Corona-19 virus in plants and its use for vaccination
JP7627447B2 (en) * 2020-04-22 2025-02-06 ポステック・リサーチ・アンド・ビジネス・ディヴェロップメント・ファウンデイション Recombinant hemagglutinin protein derived from influenza virus surface protein forming trimer and its use
WO2022260849A1 (en) 2021-06-09 2022-12-15 Nant Holdings Ip, Llc Methods and systems for producing a protein of interest in a plant
CN114891074B (en) * 2022-05-10 2023-04-11 中山大学·深圳 Seasonal influenza A universal virus-like particle and preparation method and application thereof
CN115992101B (en) * 2023-03-22 2023-07-28 深圳市卫光生物制品股份有限公司 Preparation method of influenza virus split vaccine stock solution

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098533A2 (en) * 2003-05-05 2004-11-18 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428147A (en) 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4962028A (en) 1986-07-09 1990-10-09 Dna Plant Technology Corporation Plant promotors
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US6403865B1 (en) 1990-08-24 2002-06-11 Syngenta Investment Corp. Method of producing transgenic maize using direct transformation of commercially important genotypes
UA48104C2 (en) 1991-10-04 2002-08-15 Новартіс Аг Dna fragment including sequence that codes an insecticide protein with optimization for corn, dna fragment providing directed preferable for the stem core expression of the structural gene of the plant related to it, dna fragment providing specific for the pollen expression of related to it structural gene in the plant, recombinant dna molecule, method for obtaining a coding sequence of the insecticide protein optimized for corn, method of corn plants protection at least against one pest insect
ES2248127T3 (en) 1999-10-04 2006-03-16 Medicago Inc. METHOD FOR REGULATING THE TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NIGTROGEN.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
MXPA02012254A (en) * 2000-06-23 2003-04-25 American Cyanamid Co Assembly of wild-type and chimeric influenza virus-like particles (vlps).
BRPI0410342A (en) 2003-05-05 2006-06-20 Dow Agrosciences Llc stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and processes for producing
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
CN100410378C (en) * 2005-05-09 2008-08-13 中国农业科学院生物技术研究所 Gene encoding avian influenza hemagglutinin and its plant expression vector and application
CA2615658A1 (en) * 2005-07-19 2007-01-25 Dow Global Technolgies Inc. Recombinant flu vaccines
AR060565A1 (en) * 2006-04-21 2008-06-25 Dow Agrosciences Llc VACCINE FOR THE AVIARY FLU AND METHODS OF USE
WO2007130327A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
CA2651907C (en) 2006-05-22 2016-12-20 Plant Bioscience Limited Bipartite system, method and composition for the constitutive and inducible expression of high levels of foreign proteins in plants
KR100964462B1 (en) * 2007-07-10 2010-06-16 성균관대학교산학협력단 Avian Influenza Virus Vaccine Derived from Transgenic Plant and Its Manufacturing Method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098533A2 (en) * 2003-05-05 2004-11-18 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
D'AOUST MARC-ANDRÉ ET AL: "Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.", PLANT BIOTECHNOLOGY JOURNAL DEC 2008 LNKD- PUBMED:19076615, vol. 6, no. 9, December 2008 (2008-12-01), pages 930 - 940, XP002598510, ISSN: 1467-7644 *
D'AOUST MARC-ANDRE ET AL: "The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza", PLANT BIOTECHNOLOGY JOURNAL, vol. 8, no. 5, June 2010 (2010-06-01), pages 607 - 619, XP002598511, ISSN: 1467-7644 *
GRGACIC E V L ET AL: "Virus-like particles: Passport to immune recognition", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US LNKD- DOI:10.1016/J.YMETH.2006.07.018, vol. 40, no. 1, 1 September 2006 (2006-09-01), pages 60 - 65, XP024908472, ISSN: 1046-2023, [retrieved on 20060901] *
MUSIYCHUK KONSTANTIN ET AL: "A launch vector for the production of vaccine antigens in plants", INFLUENZA AND OTHER RESPIRATORY VIRUSES, BLACKWELL PUBLISHING LTD, UK LNKD- DOI:10.1111/J.1750-2659.2006.00005.X, vol. 1, no. 1, 1 January 2007 (2007-01-01), pages 19 - 25, XP009058889, ISSN: 1750-2640, [retrieved on 20070119] *
PUSHKO ET AL: "Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice", VACCINE, ELSEVIER LTD, GB LNKD- DOI:10.1016/J.VACCINE.2005.07.098, vol. 23, no. 50, 30 December 2005 (2005-12-30), pages 5751 - 5759, XP005180698, ISSN: 0264-410X *
SAINT-JORE-DUPAS ET AL: "From planta to pharma with glycosylation in the toolbox", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 25, no. 7, 1 July 2007 (2007-07-01), pages 317 - 323, XP022116342, ISSN: 0167-7799 *
See also references of WO2010003225A1 *

Also Published As

Publication number Publication date
WO2010003225A8 (en) 2010-07-22
EP2307549A1 (en) 2011-04-13
NZ590144A (en) 2012-11-30
JP5921884B2 (en) 2016-05-24
CA2730185A1 (en) 2010-01-14
EP2570484A1 (en) 2013-03-20
KR20160049061A (en) 2016-05-04
SG187500A1 (en) 2013-02-28
MX2011000459A (en) 2011-02-23
WO2010003225A1 (en) 2010-01-14
IL210215A0 (en) 2011-03-31
RU2011105073A (en) 2012-08-20
IL210215A (en) 2013-11-28
KR20110034650A (en) 2011-04-05
EA034733B1 (en) 2020-03-13
EA201001198A1 (en) 2011-06-30
CA2730185C (en) 2016-02-09
CN102272308A (en) 2011-12-07
KR101956910B1 (en) 2019-03-12
ES2525177T3 (en) 2014-12-18
EP2570484B1 (en) 2014-09-10
JP2011527180A (en) 2011-10-27
BRPI0915896A2 (en) 2019-09-24
AU2009267759A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
EP2307549A4 (en) INFLUENZA VIRUS TYPE (VLP) PARTICLES COMPRISING HEMAGGLUTININ
EP2445928A4 (en) CHIMERIC INFLUENZA VIRUS TYPE PARTICLES COMPRISING HEMAGGLUTININ
EP1937301A4 (en) FUNCTIONAL PARTICLES SIMILAR TO INFLUENZA VIRUSES (VLP)
EP2173886A4 (en) INFLUENZA VIRUS (VLP) PSEUDO PARTICLES COMPRISING HEMAGGLUTININ (HA) PRODUCED IN A PLANT
EP2238253A4 (en) RECOMBINANT INFLUENZA PSEUDOVIRAL PARTICLES (VLPs) PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ
IL186611A0 (en) Vaccine against pandemic strains of influenza viruses
BRPI0821034A2 (en) Modified Influenza Virus
IL190906A0 (en) Influenza viruses able to infect canids, uses thereof
BRPI0716536A2 (en) production of influenza virus vaccines without the use of eggs
EP1945250A4 (en) RECOMBINANT SUBUNIT VACCINE FOR INFLUENZA VIRUS
IL239023A0 (en) Neutralizing antibodies to influenza virus
EP2525818A4 (en) IMMUNOGENIC COMPOSITION OF INFLUENZA VIRUSES
ZA200800505B (en) Modified influenza virus for monitoring and improving vaccine efficiency
FR2921928B1 (en) MONOCLONAL ANTIBODIES SPECIFIC TO INFLUENZA VIRUS HEMAGGLUTININ
AP3031A (en) Avian influenza viruses, compositions, formulations, and methods
IL195108A0 (en) Real-time detection of influenza virus
BRPI0918502A2 (en) substituted aminoindans and analogs thereof, and their pharmaceutical use
EP2723855A4 (en) INFLUENZA VIRUS MUTANTS AND USES THEREOF
EP2134360A4 (en) PURIFICATION OF VIRUS TYPE PARTICLES
CR10508A (en) NEW VIRULENCE DETERMINANT WITHIN THE STRUCTURAL GLYCROPROTEIN E2 OF THE CLASSICAL SWINE VIRUS
EP2061808A4 (en) INFLUENZA ANTIBODIES, COMPOSITIONS, AND ASSOCIATED METHODS
EP2309264A4 (en) DEVICE FOR DETECTING INFLUENZA VIRUS
WO2008049974A8 (en) Peptide vaccine for influenza virus
BRPI1014844A2 (en) swine influenza hemagglutinin variants.
SG172333A1 (en) Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110131

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

A4 Supplementary search report drawn up and despatched

Effective date: 20110809

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 7/02 20060101ALI20110803BHEP

Ipc: A61P 31/16 20060101ALI20110803BHEP

Ipc: C12N 15/29 20060101ALI20110803BHEP

Ipc: C12N 15/44 20060101ALI20110803BHEP

Ipc: A61P 37/04 20060101ALI20110803BHEP

Ipc: A61K 39/145 20060101ALI20110803BHEP

Ipc: C12N 15/82 20060101AFI20110803BHEP

Ipc: C07K 14/11 20060101ALI20110803BHEP

Ipc: C12N 7/01 20060101ALI20110803BHEP

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/82 20060101AFI20120313BHEP

Ipc: A61K 39/145 20060101ALI20120313BHEP

Ipc: C12N 7/01 20060101ALI20120313BHEP

Ipc: C12N 7/02 20060101ALI20120313BHEP

Ipc: C12N 15/29 20060101ALI20120313BHEP

Ipc: C12N 15/44 20060101ALI20120313BHEP

Ipc: C07K 14/11 20060101ALI20120313BHEP

Ipc: A61P 31/16 20060101ALI20120313BHEP

Ipc: A61P 37/04 20060101ALI20120313BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1155480

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120830

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1155480

Country of ref document: HK